To Get Help Now
Click Here
 
Today's Date:

Astellas Sued By Drug Wholesaler Over Prograf for Alleged Antitrust Violations

AddThis Social Bookmark Button

In a recently filed antitrust lawsuit, Louisiana Wholesale Drug Co., alleged that Astellas Pharma Inc., has purposefully delayed the market entry of generic versions of tacrolimus, an immune-suppressant drug sold as Prograf, for nearly two years by filing a sham petition with the Food and Drug Administration requiring safety and efficacy test for the generic versions.

The lawsuit claims “The only material difference between generic drugs and their brand name counterparts is price,” and “Astellas was keenly aware that it would lose a substantial amount of its sales of Prograf very quickly once AB-rated generics came to market.” The suit also says that by delaying the advance of generics to the market, Astellas was able to collect millions of dollars by overcharging direct purchasers of Prograf.

Prograf is used to prevent organ rejection in transplant patients. Astellas has been named in several lawsuits regarding this same issue. The lawsuit filed in U.S. District Court, District of Delaware (Wilmington) seeks to represent all direct purchasers of Prograf in unspecified damages.

breakinglawsuitnews.com disclaimer: This article: Astellas Sued By Drug Wholesaler Over Prograf for Alleged Antitrust Violations was posted on Tuesday, May 17th, 2011 at 6:39 pm at breakinglawsuitnews.com and is filed under Fraud Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.